# Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

> **NCT06690476** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking University** · enrollment: 74 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Dose escalation(IPM514 monotherapy)
- **DRUG:** Dose expansion (IPM514 combined with tislelizumab)
- **DRUG:** Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)

## Key facts

- **NCT ID:** NCT06690476
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690476, "Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06690476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*